Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01474798 | Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris | PHASE2 | COMPLETED | 11 | — | — | Feb 29, 2012 | Dec 31, 2012 | Mar 30, 2025 | 3 | United States |
Incidence and type of adverse clinical events
| Arm | Type | Description |
|---|---|---|
| RA-18C3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RA-18C3 | DRUG | For subjects weighing 27-53 kg: 100 mg (1 ml) administered every three weeks by subcutaneous injection. For subjects weighing \> 53 kg: 200 mg (2 ml) administered every three weeks by subcutaneous injection. |
Inclusion Criteria: 1. Age: ≥ 18 2. Moderate to moderately severe inflammatory acne vulgaris: * Investigator's Global Assessment grade of ≥ 3 and, * ≥ 15 inflammatory lesions (no more than 6 nodules) and, * ≥ 15 non-inflammatory lesions 3. Four week washout period for topical and oral ant...